

Hello, my name is Rob Smith. I am director of corporate responsibility at Eli Lilly and Company and serve as president of the company's philanthropic organization—the Lilly Foundation. I joined Lilly in 1996, after earning my MBA at the Kelley School of Business at Indiana University.

I will devote this podcast to sharing a few thoughts about Lilly's commitment to global corporate responsibility.

For Lilly, corporate responsibility is not just some fad that we have recently embraced—it is a fundamental part of who we are. Colonel Eli Lilly instilled the right values in our firm when he founded the company in 1876, and our values—respect for people, integrity and excellence—have guided us for over 130 years, and continue to permeate all that we do.

As we contemplate the opportunities and challenges of the 21st century, we know that the expectations society has of us—and the expectations we have of ourselves—will continue to increase. As always, Lilly will remain committed to bringing breakthrough medicines to patients—that will be our greatest contribution to society. However, we know that our obligations extend beyond just the medicines we make. In the remaining time we have together, I would like to share with you a few examples of how we are extending our work beyond just the medicines we make.

The first example is our company's comprehensive effort to treat a major global health threat—tuberculosis that is resistant to first-line treatments. This disease is called multiple drug-resistant tuberculosis or MDR-TB, for short. MDR-TB is prevalent in many areas, often impacting some of our poorest and most disadvantaged fellow human beings. The problems in treating a contagious, mutating disease like MDR-TB are significant and require the dedicated effort of many organizations. That is why we have been the catalyzing force in creating a collaborative, public/private partnership to attack this deadly disease. To date, 14 organizations around the world have joined us, and we are aligned in common cause—namely to help achieve the World Health Organization's goal of treating 800,000 MDR-TB patients by 2015.

The Lilly MDR-TB Partnership, we believe, is one of the best examples of corporate responsibility in our industry. In fact, former US Ambassador to the United Nations Richard Holbrooke said: "Lilly has set a new standard in the corporate fight against tuberculosis, and its Lilly MDR-TB Partnership in particular will serve as a superlative model for other businesses around the world to follow." If you are interested in learning more about this life-saving effort, please navigate to lillymdr-tb.com to learn more.

The second area that I would like to share with you is our company's commitment to employee engagement and volunteerism. Sharing the time, talent, and passion of our employees is, in many cases, a more valuable contribution to society than our financial donations. At Lilly, we have a strong program—called Lilly Hands and Hearts—that encourages and provides opportunities for employee volunteerism. Our highest profile effort so far this year was the Lilly Global Day of Service, during which we had over 20,000 Lilly people involved in projects that improved our communities and helped patients. For more information, including photos of this fun event, please see lillymedia.com/lillyglobaldayofservice/

Beyond this annual event, we encourage community involvement on daily basis, including having a generous policy allowing appropriate time away from work to volunteer. We know that there are many talented people that care deeply about broader societal obligations beyond their daily job responsibilities. These are exactly the kind of people we want working for us and, if you are one of these people, you will have abundant opportunities for service if you choose a career at Lilly.

Let me close by saying that we are on a journey as it relates to corporate responsibility. Whether it's helping to strengthen communities, delivering better outcomes for patients, or reducing our environmental footprint, we are proud of our company's accomplishments, but we are even more excited about what we can (and will) do in the future. Increasingly, we will focus our efforts and strive for sustainable, outcome-driven results. By doing so, we will not only generate better business performance, I believe that that Lilly—and its employees around the world—will generate lasting value for all of our stakeholders, including the patients and communities we serve.

Thank you for taking time to visit our website and for listening to this podcast.